ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 10.19B 8.79B 8.28B 7.55B 14.11B 963B 14.21B 98.06B 38.06B 492B 38.27B 37.44B 1,617B | P/E 2026 * |
-16.8x | P/E 2027 * | -32.4x |
|---|---|---|---|---|---|
| Enterprise Value | 10.09B 8.7B 8.2B 7.47B 13.96B 953B 14.07B 97.07B 37.67B 487B 37.89B 37.06B 1,601B | EV / Sales 2026 * |
11x | EV / Sales 2027 * | 7.31x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 30/06/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 31/12/2019 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 30/04/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 12/12/2005 |
| Director/Board Member | 73 | 30/04/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 24/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 10.19B | |
| -0.24% | -1.09% | +2.00% | +17.50% | 50.14B | |
| +1.16% | -4.54% | +430.83% | +526.63% | 44.85B | |
| +0.63% | +1.35% | +44.04% | +20.39% | 43.43B | |
| +0.12% | -2.84% | +7.63% | +76.68% | 41.14B | |
| +0.43% | -3.26% | +14.75% | +49.08% | 32.92B | |
| +0.02% | +7.64% | - | - | 17.56B | |
| -0.69% | -3.23% | +22.97% | +123.23% | 16.55B | |
| +0.93% | +0.63% | +16.86% | +29.29% | 14.65B | |
| -0.77% | -2.27% | +78.45% | +41.79% | 13.93B | |
| Average | +0.29% | -0.77% | +77.19% | +110.57% | 30.57B | |
| Weighted average by Cap. | +0.29% | -1.13% | +92.60% | +128.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 913M 788M 742M 676M 1.26B 86.28B 1.27B 8.79B 3.41B 44.11B 3.43B 3.35B 145B | 1.4B 1.21B 1.14B 1.04B 1.94B 132B 1.95B 13.49B 5.23B 67.71B 5.26B 5.15B 222B |
| Net income | -602M -520M -490M -446M -834M -56.91B -840M -5.8B -2.25B -29.1B -2.26B -2.21B -95.58B | -326M -281M -265M -241M -451M -30.78B -454M -3.14B -1.22B -15.74B -1.22B -1.2B -51.7B |
| Net Debt | -103M -88.83M -83.68M -76.24M -143M -9.73B -144M -991M -384M -4.97B -387M -378M -16.34B | 57.45M 49.57M 46.69M 42.54M 79.52M 5.43B 80.11M 553M 215M 2.77B 216M 211M 9.12B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
